title: [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension].
abstract: Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate essential hypertension. We selected 12 patient (7 men and 5 women, mean age 47 + 8) with left ventricular (LV) hypertrophy (men LV mass index > 130g/m2, women LV mass index > 110 g/m2) and normal (< 56 mm) LV diastolic diameter at the basal evaluation. Echocardiogram, 24-hour blood pressure monitoring and microalbuminuria have been evaluated after 3 weeks of placebo and 6 months of oral treatment with doxazosin (2 mg once daily). We evaluated: heart rate, 24-hour, day-time and night-time systolic and diastolic blood pressure, LV mass index (LVMi), peak shortening rate (-dD/dt) and peak lengthening rate (+dD/dt) of LV diameter, and systolic wall stress (ESS). At the basal evaluation +dD/dt was reduced (< 3.6 sec-1) in 9 patients; -dD:dt was normal (> 1.9 sec-1) in all. Bun and creatinine was normal before and after treatment. After treatment +dD/dt increased in all patients, with normalization in 7 patient with basal diastolic impairment. ESS and -dD/dt were normal at the basal evaluation and did not change after therapy. The % reduction of LV mass significantly correlated with % decrease of 24-hour (r = 0.71) and day-time systolic BP (r = 0.86) and 24-hour (r = 0.69) and day-time diastolic BP (r = 0.81). In conclusion, treatment with doxazosin is able to induce regression of LV hypertrophy and significantly reduce microalbuminuria.
authors.affiliation: Divisione Medicina Generale, Ospedale di Circolo, Varese.
authors.forename: M
authors.initials: M
authors.lastname: Bignotti
authors.forename: M
authors.initials: M
authors.lastname: Lamponi
mesh_terms: D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D004452:Echocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D000959:Antihypertensive Agents; D017292:Doxazosin